Streetbeat News

Stock Prices

EPRX

Eupraxia has published Phase 2 data from its SPRINGBOARD trial, which evaluates EP-104IAR for treating knee osteoarthritis. This development could impact the company's stock, EPRX.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:41 am

OCUL

Ocular Therapeutix has accelerated the SOL-1 registrational trial for Wet AMD, with full enrollment expected by the end of 2024 and topline data anticipated in Q4 2025.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:40 am

UNH

UnitedHealth Group reported strong Q3 2024 earnings, with revenue and EPS beating expectations. However, the company lowered its annual EPS guidance due to impacts from a cyberattack on Change Healthcare. Despite revenue growth, the stock is down 3.70% in premarket trading.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 11:36 am

AAPL

Apple's iPhone 16 has driven record sales for the company in Q3 2024, capturing an 18% market share, just behind Samsung. Despite mixed analyst opinions, the iPhone 16 series is expected to boost Apple's performance into 2025.

Portfolio Pulse from Rounak Jain

October 15, 2024 | 11:35 am

ZENA

ZenaTech's subsidiary, ZenaDrone, has initiated a US trial for its IQ Nano Drone. This development marks a significant step in ZenaTech's expansion into the US market, potentially impacting its market presence and stock performance.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:35 am

SCHW

Charles Schwab shares rose due to strong Q3 financial results, with a 27% year-over-year increase in total client assets.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:34 am

GS

Goldman Sachs shares rose following the release of their Q3 earnings report, which exceeded expectations in both adjusted EPS and sales.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:28 am

GS

Goldman Sachs CEO emphasizes the company's focus on leveraging its strengths in talent, execution, and risk management to serve clients and deliver for shareholders amidst a complex environment.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:28 am

EXP

TRS

As of October 15, 2024, TriMas Corp (TRS) and Eagle Materials Inc (EXP) are considered overbought in the materials sector, with RSI values above 70. Both stocks have shown significant price gains recently, but investors may want to be cautious due to their overbought status.

Portfolio Pulse from Avi Kapoor

October 15, 2024 | 11:28 am

GS

Goldman Sachs reported Q3 2024 earnings per share of $8.40, surpassing the analyst estimate of $7.03. The company's sales reached $12.70 billion, exceeding the expected $11.87 billion and marking a 7.47% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 11:27 am